Krystal 生物技术内幕出售股票价值16.3M美元,收入丰厚,股票不断上涨。 Krystal Biotech insider sold shares worth $16.3M amid strong earnings and rising stock.

2026年2月24日至26日, Krystal生物科技主任Daniel Janney 连续数天出售60 161股股票, 筹集了约1 630万美元, On February 24–26, 2026, Daniel Janney, a Krystal Biotech director, sold 60,161 shares across multiple days, raising about $16.3 million, reducing his stake by 8.34%. 一个独立内部人出售700股,价值192 500美元。 A separate insider sold 700 shares for $192,500. 2月26日库存增至276.36美元, The stock rose to $276.36 on February 26 amid below-average volume. 2月17日,Krystal Biotech报告Q4收入丰厚,EPS为170美元,收入为1.0711亿美元,超过估计数。 Krystal Biotech reported strong Q4 earnings on February 17, with $1.70 EPS and $107.11 million in revenue, surpassing estimates. 该公司致力于开发针对罕见皮肤疾病如营养不良性表皮松解性肥厚症的基因疗法，市值为80.8亿美元，市场共识评级为“中等买入”，目标价格为326.25美元。 The company, developing gene therapies for rare skin diseases like dystrophic epidermolysis bullosa, has a market cap of $8.08 billion and a consensus "Moderate Buy" rating with a $326.25 price target.